Article Information
History
- December 22, 2022.
Article Versions
- Version 1 (October 18, 2022 - 08:55).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- 1Japan Marine United Corporation, Kure Shipyard, Kure, Japan
- 2Non-profit Organization “Japan Institute of Pharmacovigilance (Med Check)”, Osaka, Japan
- ↵*Correspondence to: Rokuro Hama,
Non-profit Organization “Japan Institute of Pharmacovigilance (Med Check)”, Email:
gec00724{at}nifty.com
CONTRIBUTIONS: SW proposed to conduct the study, RH and SW designed the study. Both authors independently converted the pdf data disclosed by the Japanese government into excel files and confirmed data matched. Then data collection, classification, and analyses were done first by the SW and later confirmed by RH, with any discrepancies being discussed and decided by both parties. SW and RH contributed equally to this study and reviewed the final manuscript.
Posted December 22, 2022.
SARS-CoV-2 vaccine and increased myocarditis mortality risk: A population based comparative study in Japan
